Agilent Technologies, Inc. (NYSE: A) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 29.25 | EPS (ttm) | 4.99 | Insider Own | 0.57% | Shs Outstand | 282.43M | Perf Week | 5.49% |
| Market Cap | 41.23B | Forward P/E | 22.11 | EPS next Y | 6.60 | Insider Trans | -0.10% | Shs Float | 281.47M | Perf Month | 9.27% |
| Enterprise Value | 42.77B | PEG | 1.29 | EPS next Q | 1.49 | Inst Own | 61.67% | Short Float | 2.68% | Perf Quarter | 23.03% |
| Income | 1.41B | P/S | 5.70 | EPS this Y | 21.64% | Inst Trans | - | Short Ratio | 3.20 | Perf Half Y | 12.60% |
| Sales | 7.23B | P/B | 5.80 | EPS next Y | 8.98% | ROA | 10.82% | Short Interest | 7.54M | Perf YTD | 7.28% |
| Book/sh | - | P/C | 28.45 | EPS next 5Y | 9.83% | ROE | 20.84% | 52W High | 162.61 -8.92% | Perf Year | 28.91% |
| Cash/sh | - | P/FCF | 32.82 | EPS past 3/5Y | 3.02% 14.72% | ROIC | 12.54% | 52W Low | 109.94 34.72% | Perf 3Y | 14.30% |
| Dividend Est. | 1.02 (0.69%) | EV/EBITDA | 21.80 | Sales past 3/5Y | 0.48% 5.41% | Gross Margin | 53.00% | Volatility | 2.61% 2.67% | Perf 5Y | -4.74% |
| Dividend TTM | 1.01 (0.68%) | EV/Sales | 5.91 | EPS Y/Y TTM | 12.42% | Oper. Margin | 21.50% | ATR (14) | 3.93 | Perf 10Y | 207.24% |
| Dividend Ex-Date | Jun 30, 2026 | Quick Ratio | 1.62 | Sales Y/Y TTM | 11.09% | Profit Margin | 19.55% | RSI (14) | 69.83 | Recom | 2.22 |
| Dividend Gr. 3/5Y | -11.27% 6.62% | Current Ratio | 2.10 | EPS Q/Q | 13.74% | SMA20 | 6.17% | Beta | 1.22 | Target Price | 153.25 |
| Payout | 20.16% | Debt/Eq | 0.47 | Sales Q/Q | 10.01% | SMA50 | 8.66% | Rel Volume | 0.65 | Prev Close | 145.97 |
| Employees | 18,100 | LT Debt/Eq | 0.45 | Earnings | Aug 26 | SMA200 | 11.41% | Avg Volume | 2.34M | Price | 148.10 |
| IPO Date | Nov 18, 1999 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.79% 2.03% | Net Debt/EBITDA | 0.79 | Volume | 1,525,050 | Change | 1.46% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $160 → $148 |
| Jun-11-26 | Downgrade | Piper Sandler | Overweight → Neutral | $150 |
| Jun-03-26 | Reiterated | HSBC | Buy | $180 → $165 |
| May-28-26 | Reiterated | Robert W. Baird | $156 → $158 | |
| May-28-26 | Reiterated | Wells Fargo | Overweight | $165 → $160 |
| May-28-26 | Reiterated | RBC Capital | Outperform | $153 → $155 |
| May-28-26 | Upgrade | B of A Securities | Neutral → Buy | |
| May-26-26 | Initiated | RBC Capital | Outperform | $153 |
| May-26-26 | Reiterated | Robert W. Baird | $155 → $156 | |
| Apr-14-26 | Reiterated | Barclays | Overweight | $165 → $140 |
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 10/31/2025 | FY 2024 10/31/2024 | FY 2023 10/31/2023 | FY 2022 10/31/2022 | FY 2021 10/31/2021 | FY 2020 10/31/2020 | FY 2019 10/31/2019 | FY 2018 10/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 7,232 | 6,948 | 6,510 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3,399 | 3,305 | 2,975 | — | — | — | — | — | — | |
| Gross Profit | 3,833 | 3,643 | 3,535 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,786 | 1,709 | 1,518 | — | — | — | — | — | — | |
| Research and Development | 473 | 455 | 479 | — | — | — | — | — | — | |
| Other Operating Expense | 19 | 0 | 50 | — | — | — | — | — | — | |
| Operating Income | 1,555 | 1,479 | 1,488 | — | — | — | — | — | — | |
| Interest Expense | 105 | 112 | 96 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 130 | 68 | 129 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,580 | 1,435 | 1,521 | — | — | — | — | — | — | |
| Income Taxes | 166 | 132 | 232 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,414 | 1,303 | 1,289 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,414 | 1,303 | 1,289 | — | — | — | — | — | — | |
| Net Income | 1,414 | 1,303 | 1,289 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.99 | 4.59 | 4.44 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.99 | 4.59 | 4.44 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.98 | 4.57 | 4.43 | — | — | — | — | — | — | |
| EBITDA | 1,962 | 1,835 | 1,874 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 29.74 | 32.03 | 29.42 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.80 | 5.96 | 5.80 | — | — | — | — | — | — | |
| Gross Margin | 53.00 | 52.43 | 54.30 | — | — | — | — | — | — | |
| Operating Margin | 21.50 | 21.29 | 22.86 | — | — | — | — | — | — | |
| Net Margin | 19.55 | 18.75 | 19.80 | — | — | — | — | — | — | |
| Shares Outstanding | 283 | 283 | 290 | — | — | — | — | — | — | |
| Market Capitalization | 41,914 | 41,420 | 37,790 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Dolsten Mikael | Director | May 29 '26 | Sale | 135.42 | 1,600 | 216,672 | 5,548 | Jun 02 |
| Dolsten Mikael | Director | Dec 01 '25 | Sale | 149.81 | 2,600 | 389,511 | 4,973 | Dec 03 |
| Gonsalves Rodney | V.P., Corporate Controller | Nov 26 '25 | Sale | 154.99 | 3,000 | 464,956 | 31,846 | Dec 01 |
| MCDONNELL PADRAIG | President and CEO | Nov 18 '25 | Sale | 143.24 | 911 | 130,492 | 32,058 | Nov 20 |
| MCDONNELL PADRAIG | President and CEO | Nov 12 '25 | Option Exercise | 109.86 | 12,490 | 1,372,151 | 45,938 | Nov 14 |
| MCDONNELL PADRAIG | President and CEO | Nov 12 '25 | Sale | 150.00 | 12,490 | 1,873,500 | 33,448 | Nov 14 |
| MCDONNELL PADRAIG | President and CEO | Sep 02 '25 | Sale | 124.88 | 2,000 | 249,760 | 33,448 | Sep 04 |
| MCDONNELL PADRAIG | President and CEO | Aug 01 '25 | Sale | 113.45 | 2,000 | 226,900 | 35,448 | Aug 04 |
| MCDONNELL PADRAIG | President and CEO | Jul 01 '25 | Sale | 117.44 | 1,508 | 177,100 | 37,448 | Jul 03 |
| Brown Judy L | Director | Jun 18 '25 | Sale | 116.53 | 8 | 904 | 1,677 | Jun 23 |
| Podolsky Daniel K | Director | Mar 31 '25 | Sale | 116.46 | 1,819 | 211,844 | 35,737 | Apr 02 |
| Gonsalves Rodney | V.P., Corporate Controller | Mar 17 '25 | Sale | 121.98 | 1,908 | 232,691 | 21,786 | Mar 18 |
| Rataj Sue H. | Director | Mar 06 '25 | Sale | 126.38 | 6,971 | 881,009 | 19,640 | Mar 07 |
| MCDONNELL PADRAIG | President and CEO | Jan 21 '25 | Sale | 150.00 | 1,911 | 286,650 | 39,652 | Jan 23 |
| MCDONNELL PADRAIG | President and CEO | Sep 27 '24 | Sale | 150.00 | 47 | 7,050 | 24,071 | Sep 30 |